DoD Peer Reviewed Cancer, Career Development Award | W81XWH 21 PRCRP CDA

Opportunity Information: Apply for W81XWH 21 PRCRP CDA

The Department of Defense (DoD) Peer Reviewed Cancer Research Program (PRCRP) Career Development Award (CDA) is designed to strengthen the cancer research workforce by helping early-career investigators build the skills, track record, and research foundation needed to become independent leaders in the field. The program emphasizes discovery-oriented, impactful cancer research while placing equal weight on the applicant's career trajectory and development plan. In FY21, the PRCRP limited this funding mechanism to a single pathway: the Career Development Award - Fellow Option. The alternative pathway, the Virtual Cancer Center Scholar Option, was not offered that year, so all CDA applicants had to apply under the Fellow Option.

A central feature of this opportunity is that the early-career investigator serves as the Principal Investigator (PI), and the application is expected to center on the PI's research vision and career development needs rather than on a senior mentor's laboratory program. The award is structured to support research projects that are scientifically sound and logically justified even if they are still early-stage. Preliminary data are explicitly not required, which lowers a common barrier for newer independent investigators proposing innovative ideas. That said, the proposal still has to show strong scientific reasoning and a clear rationale for why the approach is credible and worth pursuing. If an applicant chooses to include preliminary data, reviewers will evaluate it, and one intended outcome of the award is to generate robust preliminary findings that can support future, larger-scale grants and sustained research independence.

Eligibility and career stage requirements are tightly defined. The PI must be an early-career researcher or physician-scientist who is within seven years of completing their terminal degree by the application deadline, with certain exclusions allowed for time spent in residency, clinical training, or family medical leave. Importantly, time spent as a postdoctoral fellow does not stop the clock, and postdoctoral fellows are not eligible because the mechanism is intended for investigators who are already independent. Reviewers consider both the PI's accomplishments and the proposed research in relation to the PRCRP's specified FY21 topic areas, and they also consider whether the PI has already received meaningful career development support. The Fellow Option is meant for candidates who have received only nominal career development funding (beyond institutional startup support), so an applicant's prior and current career development awards can influence how reviewers judge the need for additional developmental resources.

Mentorship is required but framed as guidance for an independent investigator rather than training for a trainee. Each Fellow must designate a Career Guide who is an experienced cancer researcher with a strong publication and funding record. The Career Guide must also demonstrate a genuine commitment to advancing the Fellow's career, which aligns with the program's goal of producing durable, independent research careers. Alongside the research plan, applicants must submit a detailed Career Development Plan developed with input from the Career Guide. This plan needs to lay out a concrete strategy for building skills, expertise, and professional readiness to lead at the forefront of cancer research, specifically tied to at least one of the FY21 PRCRP topic areas.

Institutional commitment is another major review and eligibility consideration. Because the award is explicitly about career development and establishing independence, the PI's organization must show tangible support, including confirmation of laboratory space and at least 50 percent protected time devoted to cancer research. This requirement signals that the DoD expects the recipient to have sufficient time and infrastructure to make real progress both scientifically and professionally during the award period, rather than trying to fit the work around heavy clinical or teaching loads.

The PRCRP also places strong emphasis on real-world significance and defense-related relevance. Applicants must clearly explain the potential impact of the work on cancer research and/or patient care, with a focus on accelerating promising ideas toward clinical application if the research succeeds. In addition, the proposed project must address at least one FY21 PRCRP Military Health Focus Area and be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the broader American public. In other words, the science needs to matter not only in a general oncology context but also in a way that connects to military health needs and outcomes.

From an administrative standpoint, this opportunity was released by the Department of Defense, Department of the Army, through USAMRAA, under Funding Opportunity Number W81XWH-21-PRCRP-CDA. It falls under CFDA 12.420 and uses grant and cooperative agreement funding instruments. Eligibility was listed as unrestricted (open to many entity types, subject to any additional eligibility notes in the full announcement). The original closing date was August 18, 2021, and the program anticipated making roughly 17 awards. The published award ceiling in the summary data is listed as 0, which typically indicates that applicants needed to rely on the full announcement for budget limits and allowable costs rather than the high-level listing.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Cancer, Career Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 24, 2021.
• Applicants must submit their applications by Aug 18, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 17 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PRCRP CDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: